| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3064978 | Journal of Neuroimmunology | 2009 | 13 Pages |
Abstract
The neuroregulatory activities of PMS-601, a platelet activating factor antagonist, were investigated in laboratory and animal models of HIV-1 encephalitis (HIVE). For the former, PMS-601 reduced monocyte-derived macrophage pro-inflammatory secretions, multinucleated giant cell (MGC) formation, and neuronal loss independent of antiretroviral responses. PMS-601 treatment of HIVE severe combined immunodeficient mice showed reduced microgliosis, MGCs and neurodegeneration. These observations support the further development of PMS-601 as an adjunctive therapy for HIV-1 associated neurocognitive disorders.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Dawn Eggert, Prasanta K. Dash, Nawal Serradji, Chang-Zhi Dong, Pascal Clayette, Francoise Heymans, Huanyu Dou, Santhi Gorantla, Harris A. Gelbard, Larisa Poluektova, Howard E. Gendelman,